tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Caufield, 40 are a BUY (97.56%), 1 are a HOLD (2.44%).
Analyst Matthew Caufield works with a stock forecast success ratio of 12.96% fulfilled within 31.22 days on average. Previously, Matthew Caufield worked at HC WAINWRIGHT.
Matthew Caufield’s has documented 81 price targets and ratings displayed on 9 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on LYRA, Lyra Therapeutics at 01-May-2024.
Analyst best performing recommendations are on ISEE (IVERIC BIO).
The best stock recommendation documented was for GMTX (GEMINI THERAPEUTICS) at 12/15/2021. The price target of $20 was fulfilled within 34 days with a profit of $9.9 (33.11%) receiving and performance score of 9.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
10
$5.84 (140.38%)
15
1 months 2 days ago
0/6 (0%)
$6.73 (205.81%)
Buy
8
$3.84 (92.31%)
25
6 months 17 days ago
0/10 (0%)
$6.16 (334.78%)
Hold
14
6 months 17 days ago
2/3 (66.67%)
$6.42 (84.70%)
362
Buy
2 years 4 months 7 days ago
0/1 (0%)
$9.48 (75.72%)
Buy
20
$15.84 (380.77%)
20
4 years 10 months 8 days ago
0/4 (0%)
$13.77 (221.03%)
Which stock is Matthew Caufield is most bullish on?
Which stock is Matthew Caufield is most reserved on?
What Year was the first public recommendation made by Matthew Caufield?
